NewAmsterdam Obicetrapib: CETP Clears EU, PREVAIL Bet

The CETP inhibitor class is the most expensive graveyard in cardiometabolic drug development. Pfizer killed torcetrapib in 2006 after the ILLUMINATE trial showed increased cardiovascular events and mortality, driven by off-target effects on aldosterone, cortisol, and endothelin-1. Roche killed dalcetrapib in 2012 after dal-OUTCOMES showed no benefit and no meaningful LDL-C reduction. Eli Lilly killed evacetrapib in 2015 after ACCELERATE showed a 37% LDL-C reduction and 130% HDL-C increase that failed to translate into fewer cardiovascular events. Merck pushed anacetrapib through the REVEAL trial to completion in 2017, found a modest coronary benefit, and then abandoned the program because the drug accumulated in adipose tissue with a half-life of 550 days.

Four programs. Billions in R&D. Zero approved drugs. Until now.

On July 23, 2026, the EMA’s Committee for Medicinal Products for Human Use adopted positive opinions recommending marketing authorization for Ubeslo (obicetrapib monotherapy, 10mg) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) for adults with primary hypercholesterolemia or mixed dyslipidemia. NewAmsterdam Pharma, a Dutch biotech listed on Nasdaq as NAMS, developed the drug. Menarini holds EU commercialization rights. European Commission decisions are expected in the second half of 2026, with launches in Germany and the UK by the fourth quarter.

The Clinical Data Behind the EU Decision

The EU filing rests on three Phase 3 trials. BROADWAY (NCT05142722) enrolled over 2,500 patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia, on top of maximally tolerated lipid-lowering therapy. The primary endpoint was the least-squares mean percent change in LDL-C from baseline to day 84. Obicetrapib 10mg achieved a 33% reduction (p<0.0001). The mean baseline LDL-C was approximately 100 mg/dL despite nearly 70% of patients being on high-intensity statins.

BROOKLYN (NCT05425745) tested the same drug in HeFH patients. The primary endpoint hit a 36.3% reduction at day 84 (p<0.0001), sustained at 41.5% at day 365 (p<0.0001). Baseline LDL-C was 123 mg/dL with 79% on high-intensity statins, 54% on ezetimibe, and 14% on PCSK9 inhibitors. This is a heavily pretreated population that still had elevated cholesterol.

TANDEM tested the fixed-dose combination with ezetimibe and showed a 40.1% LDL-C reduction at 8 weeks (p<0.0001).

The safety profile is what separates obicetrapib from its dead predecessors. Torcetrapib raised blood pressure and caused electrolyte disturbances. Anacetrapib accumulated in tissue for years. Obicetrapib has a half-life of roughly two weeks and showed a side effect profile similar to placebo across all Phase 3 trials. No off-target aldosterone or endothelin-1 signals. No blood pressure elevation. The ClinicalTrials.gov listing for the ongoing PREVAIL trial confirms the design.

There is also an exploratory signal that matters. BROADWAY showed a 21% reduction in major adverse cardiovascular events at one year, favoring obicetrapib. This was not the primary endpoint and was not powered for statistical significance. But it is the first time a CETP inhibitor has shown a MACE signal in the right direction, and it is the signal NewAmsterdam is hanging the US strategy on.

The EU-US Regulatory Divergence

This is where the story gets interesting and where the investment thesis gets risky.

The EU accepted LDL-C lowering as a surrogate endpoint for approval. The EU regulatory framework allows approval based on lipid biomarker improvement in a population with unmet need, particularly when the drug is well tolerated and the mechanism is understood. The positive CHMP opinion reflects that framework.

The FDA is more cautious. No PDUFA date has been assigned for obicetrapib in the US. The FDA wants cardiovascular outcomes data before approving a CETP inhibitor, and the history of the class explains why. Torcetrapib lowered LDL-C and raised HDL-C, then killed people. Evacetrapib lowered LDL-C by 37% and raised HDL-C by 130%, then showed no CV benefit. The FDA has seen this movie three times and does not want a fourth screening without hard outcomes data.

PREVAIL (NCT05202509) is the outcomes trial that will determine the US path. It enrolled 9,541 patients with established ASCVD whose LDL-C was not adequately controlled despite maximally tolerated lipid-lowering therapy. The primary endpoint is MACE: cardiovascular death, myocardial infarction, stroke, and non-elective coronary revascularization. The follow-up period is 30 months after the last patient was randomized. Enrollment completed in April 2024. An interim analysis is expected in the fourth quarter of 2026.

If PREVAIL is positive, NAMS gets a second catalyst toward a US filing. If PREVAIL is negative, the EU approval stands but the US market, which is roughly 40% of the global lipid-lowering market, stays closed. The stock is pricing in a PREVAIL win that has not happened yet.

The Valuation and the Comps

NewAmsterdam closed at $29.64 on July 24, with a market cap of roughly $3.47 billion. The stock is down about 9% year-to-date, from $32.41 on January 20. Notably, the stock dropped from $32.34 on July 21 to $29.64 on July 24, the week of the CHMP opinion. That is a “sell the news” reaction on a catalyst that should be positive, and it tells you something about how much of this approval was already priced in.

The valuation problem is straightforward. NAMS has zero revenue. The EU launch will not generate material revenue until late 2026 at the earliest, and Menarini takes a significant cut as the commercialization partner. The US market is gated on PREVAIL. So at $3.47 billion, you are paying for a pre-revenue company whose only near-term revenue stream is a partnered EU launch in a competitive market.

Here are the comps. Amgen’s Repatha, the dominant PCSK9 inhibitor, generated $656 million in Q1 2025 revenue and roughly $2.2 billion annually. Novartis’s Leqvio, the siRNA PCSK9 inhibitor, was the fastest-growing product in Novartis’s portfolio with 112% revenue growth in 2024. The total PCSK9 inhibitor market was valued at roughly $2.9 to $3.2 billion in 2025 and is projected to grow to $18 billion by 2035. That is the competitive frame for obicetrapib: an oral once-daily pill entering a market dominated by injectable biologics with established reimbursement pathways.

The bull case is that an oral CETP inhibitor at 10mg once daily is more convenient than a monthly or twice-yearly injection, and that the LDL-C reduction of 33 to 41% is competitive with PCSK9 inhibitors without the cold-chain or injection burden. If obicetrapib captures even 10% of the projected 2035 PCSK9-adjacent market, that is $1.8 billion in peak revenue. At a 3x peak-sales multiple, that gets you close to the current market cap. But that assumes PREVAIL is positive, the US approves, and the launch executes. Three conditional probabilities multiplied together.

The comp that gives me pause is what happened to the oral PCSK9 inhibitor Lipfendra. Merck won FDA approval for an oral PCSK9 inhibitor, and the stock reaction was muted because the market already understood that oral lipid-lowering is a crowded, margin-compressed space. Obicetrapib would enter the same dynamic. Ezetimibe is generic. Statins are generic. PCSK9 inhibitors are fighting for formulary placement. A CETP inhibitor with a MACE signal from PREVAIL could differentiate, but without that signal, it is another LDL-C lowering agent in a market that does not need more of them.

The Specific Risk

The PREVAIL interim in Q4 2026 is the binary event. Here is the uncomfortable math. The CETP class has a 0-for-3 record on cardiovascular outcomes trials. Torcetrapib was toxic. Dalcetrapib was inert. Evacetrapib lowered LDL-C and showed no benefit. Anacetrapib showed a modest benefit that Merck deemed insufficient to commercialize. The prior probability of a positive PREVAIL, based on class history alone, is low.

Obicetrapib is mechanistically cleaner than its predecessors. The half-life is shorter. The safety profile is better. The LDL-C reductions are real and durable. But the history of cardiovascular drug development is full of drugs that lowered LDL-C and did not reduce events. The FDA’s caution is not bureaucratic inertia. It is empirically grounded.

If PREVAIL is negative, NAMS drops to whatever the EU-only revenue stream is worth. Menarini-partnered, limited EU launch, no US market, competing against generic statins and entrenched PCSK9 inhibitors. That is a $1 to $1.5 billion company, not a $3.5 billion one. The downside is 50 to 60%. The upside, if PREVAIL is positive and the US approves, is a $6 to $8 billion company with a first-in-class oral CETP inhibitor and a MACE label. The asymmetry is real, but it hinges on a trial that has not read out.

The Verdict

The EU CHMP opinion is a regulatory milestone. It is the first CETP inhibitor to clear a major regulator in 20 years of trying. But the market reaction tells the story: the stock fell on the news. At $3.47 billion, NAMS is pricing in a PREVAIL win, a US approval, and a successful launch against entrenched PCSK9 competition. I would not pay that price for a binary bet on a cardiovascular outcomes trial in a class with a 0-for-3 record.

The trade I would watch: wait for the PREVAIL interim in Q4 2026. If it is positive, buy the stock on the pullback that will follow the initial spike. If it is negative, the stock drops 50% and you avoided it. The Arrowhead plozasiran Phase 3 analysis and the Alnylam nucapsiran hypertension RNAi analysis cover the same principle: in cardiometabolic drug development, the outcomes trial is the only thing that matters, and everything before it is option value. NewAmsterdam is selling you that option at a price that assumes the outcome is already decided. It is not.